Endomatic

Endovascular Left Atrial Appendage Closure Device

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in June 2018 by Boaz Schwarz, Endomatic operates with 1–10 employees. The company has raised $1 million across four funding rounds from one investor.

Business overview

Endomatic is a Health Tech & Life Sciences company focused on developing a breakthrough endovascular Left Atrial Appendage (LAA) closure device to prevent strokes. The company's core technology aims to eliminate the risk of device-related thrombus (DRT), a significant concern in current LAA occlusion procedures. Endomatic serves the healthcare industry, specifically targeting interventional cardiologists and electrophysiologists, and operates within the Medical Devices and Medical Treatment & Therapeutics sectors.

Log in to access full profile

Company Intelligence Q&A

What is Endomatic's primary focus?
Endomatic is focused on developing an endovascular Left Atrial Appendage (LAA) closure device to prevent strokes, particularly in patients with Atrial Fibrillation.
Who founded Endomatic?
Endomatic was founded by Boaz Schwarz in June 2018.
What is the key innovation of Endomatic's technology?
Endomatic's patented technology aims to eliminate the risk of device-related thrombus (DRT), a common concern with existing LAA closure devices, due to its non-thrombogenic nature.
Log in to access full profile